Gastrointestinal Cancer | Specialty

Dr. Choti on Future Treatment of Patients With Stage IV Pancreatic Cancer

January 21st 2020

Michael A. Choti, MD, discusses the future of treatment for patients with stage IV pancreatic cancer.

Tabernero Finds New Paths in Gastrointestinal Treatment Landscape

January 19th 2020

Josep Tabernero, MD, PHD, MSc, is best known for applying translational research against gastrointestinal tumors, with particular focus on colorectal cancer.

FDA Approvals Boost Competition in Treatment Landscapes

January 18th 2020

Therapeutic developments in cancer were rewarded with a wave of approvals in 2019.

Dr. Ribeiro on Criteria for Determining Borderline Resectability in Pancreatic Cancer

January 18th 2020

Afonso Ribeiro, MD, medical director of Advanced Endoscopy and Gastroenterology at Memorial Healthcare System, discusses the criteria that can be used to determine whether a patient with pancreatic cancer is borderline resectable.

Investigators Test Breakthrough-Designated Triplet in First-Line CRC

January 17th 2020

Investigators hope to answer a potentially paradigm-changing question in the phase II ANCHOR-CRC study (NCT03693170) of BRAF V600E–mutant colorectal cancer (CRC): Can the benefit observed with a targeted triplet in latestage disease extend to the first line?

Dr. Ferraro on the Use of Molecular Profiling in Pancreatic Cancer

January 17th 2020

Pablo Ferraro, MD, discusses the use of molecular profiling in pancreatic cancer.

Molecular Testing for Colon Cancer Falls Far Short of the Guidelines

January 16th 2020

Between 2013 and 2017, just 40% of patients with metastatic colon cancer received guideline-recommended biomarker testing that could have improved treatment decisions, according to findings from a retrospective study. Results also showed that adherence to evidence-based recommendations for genotyping was poor in academic and community settings alike.

Dr. Hussein on the Evolution of Treatment in HCC

January 16th 2020

Atif Hussein, MD, discusses the evolution treatment in hepatocellular carcinoma.

Dr. Lockhart on Strategies for Targeting the RAS/RAF/MEK/ERK Pathway in CRC

January 14th 2020

A. Craig Lockhart, MD, MHS, professor and associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses investigational strategies targeting the RAS/RAF/MEK/ERK pathway in colorectal cancer (CRC).

Novel Agents Generate Excitement in Advanced HCC, Cholangiocarcinoma

January 14th 2020

Atif Hussein, MD, discusses how the treatment of patients with hepatocellular carcinoma and cholangiocarcinoma has evolved in recent years.

Role of Immunotherapy Agents Grows in Metastatic Colorectal Cancer

January 11th 2020

The standard of care in the second line for patients with mismatch repair–deficient metastatic colorectal cancer has shifted to favor therapy utilizing immunotherapeutic agents, according to Howard Hochster, MD.

Dr. Janjigian on Data With Atezolizumab/Bevacizumab Combo in HCC

January 11th 2020

Yelena Y. Janjigian, MD, discusses the improvement in efficacy and toxicity with patients with hepatocellular carcinoma who are treated with bevacizumab and atezolizumab when compared with sorafenib.

HER2+ Breast Cancer: Future Treatment Landscape

January 11th 2020

Practical Advice on Treating HER2+ Metastatic Breast Cancer

January 11th 2020

Targeting HER2 Outside of Breast Cancer

January 11th 2020

Combining Anti-HER2 Agents With Immunotherapy for HER2+ mBC

January 11th 2020

Emerging Agents for HER2+ mBC: Targeted Therapeutics

January 11th 2020

Emerging Agents for HER2+ mBC: HER2CLIMB and SOPHIA Trials

January 11th 2020

Evolving Role of Trastuzumab Deruxtecan in HER2+/HER2-Low mBC

January 11th 2020

HER2+ mBC: Addressing ILD in the DESTINY-Breast01 Study

January 11th 2020